https://orcid.org/0000-0002-3843-642X
Key Points
VWD type 1 may be associated with clinically significant bleeding symptoms and reduced quality of life, while prophylactic treatment is rare.
Subcutaneous injection of nanobody KB-V13A12 increases endogenous VWF levels twofold for 10 days, and restores hemostasis in VWD type 1 mice.
Subjects:
Thrombosis and Hemostasis
Abstract
von Willebrand disease (VWD) type 1 is a bleeding disorder characterized by a quantitative deficiency of functional von Willebrand factor (VWF). We designed a novel bispecific nanobody, named KB-V13A12, that aims to increase endogenous VWF levels by bridging it to albumin. KB-V13A12 comprises 2 single-domain antibodies, 1 targeting VWF and 1 targeting albumin. VWF bound efficiently to the albumin/KB-V13A12 complex (2.0 ± 0.4 nM) in immunosorbent assays, and binding was stable at pH 5.6 and 7.4. VWF ristocetin activity and factor VIII binding remained unaffected in the presence of a 100- to 200-fold molar excess of KB-V13A12/albumin. Humanized VWD type 1 mice were used for in vivo analysis. A single subcutaneous dose of KB-V13A12 (5 mg/kg) was associated with a nanobody half-life of 3.0 ± 0.7 days, and dose-dependently increased VWF in VWD type 1 mice 1.4- to 2.1-fold for up to 14 days. Factor VIII activity was also increased during this period. The VWF propeptide/VWF antigen ratio (a marker for VWF clearance) was significantly reduced in the presence of KB-V13A12, suggesting that delayed clearance contributes to increased VWF levels. Clearance experiments in wild-type mice using recombinant VWF preincubated with KB-V13A12 indeed confirmed a prolonged survival, while this prolongation was absent in FcRn-deficient mice. Finally, treatment with KB-V13A12 resulted in a significantly improved bleeding tendency in VWD type 1 mice when using the saphenous vein puncture model. In conclusion, KB-V13A12 is a bispecific nanobody that efficiently increases functional levels of endogenous VWF, and could be a therapeutic option to treat VWD type 1.
Subjects:
Thrombosis and Hemostasis
References
1.
Leebeek
FW
, Eikenboom
JC
. Von Willebrand’s disease
. N Engl J Med
. 2016
;375
(21
):2067
-2080
.2.
Seidizadeh
O
, Eikenboom
JCJ
, Denis
CV
, et al. von Willebrand disease
. Nat Rev Dis Primers
. 2024
;10
(1
):51
.3.
Seidizadeh
O
, Cairo
A
, Baronciani
L
, Valenti
L
, Peyvandi
F
. Population-based prevalence and mutational landscape of von Willebrand disease using large-scale genetic databases
. NPJ Genom Med
. 2023
;8
(1
):31
.4.
Seidizadeh
O
, Cairo
A
, Oriani
C
, Peyvandi
F
. Global prevalence and ethnic diversity of von Willebrand disease: an updated population-based genetic analysis
. Research Square
. 2025
;9
(1
):102682
.5.
Du
P
, Bergamasco
A
, Moride
Y
, Truong Berthoz
F
, Özen
G
, Tzivelekis
S
. Von Willebrand disease epidemiology, burden of illness and management: a systematic review
. J Blood Med
. 2023
;14
:189
-208
.6.
Srivaths
L
, Minard
CG
, O’Brien
SH
, et al. The spectrum and severity of bleeding in adolescents with low von Willebrand factor-associated heavy menstrual bleeding
. Blood Adv
. 2020
;4
(13
):3209
-3216
.7.
Lavin
M
, Aguila
S
, Schneppenheim
S
, et al. Novel insights into the clinical phenotype and pathophysiology underlying low VWF levels
. Blood
. 2017
;130
(21
):2344
-2353
.8.
Seidizadeh
O
, Ciavarella
A
, Baronciani
L
, et al. Clinical and laboratory presentation and underlying mechanism in patients with low VWF
. Thromb Haemost
. 2024
;124
(4
):340
-350
.9.
Suvada
K
, Plantinga
L
, Vaughan
CP
, et al. Comorbidities, age, and polypharmacy limit the use by US older adults with nocturia of the only FDA-approved drugs for the symptom
. Clin Ther
. 2020
;42
(12
):e259
-e274
.10.
Barr
RD
, Sek
J
, Horsman
J
, et al. Health status and health-related quality of life associated with von Willebrand disease
. Am J Hematol
. 2003
;73
(2
):108
-114
.11.
de Wee
EM
, Mauser-Bunschoten
EP
, Van Der Bom
JG
, et al. Health-related quality of life among adult patients with moderate and severe von Willebrand disease
. J Thromb Haemost
. 2010
;8
(7
):1492
-1499
.12.
Govorov
I
, Ekelund
L
, Chaireti
R
, et al. Heavy menstrual bleeding and health-associated quality of life in women with von Willebrand’s disease
. Exp Ther Med
. 2016
;11
(5
):1923
-1929
.13.
Xu
Y
, Deforest
M
, Grabell
J
, Hopman
W
, James
P
. Relative contributions of bleeding scores and iron status on health-related quality of life in von Willebrand disease: a cross-sectional study
. Haemophilia
. 2017
;23
(1
):115
-121
.14.
Roberts
JC
, Kulkarni
R
, Kouides
PA
, et al. Depression and anxiety in persons with Von Willebrand disease
. Haemophilia
. 2023
;29
(2
):545
-554
.15.
Sockolosky
JT
, Szoka
FC
. The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy
. Adv Drug Deliv Rev
. 2015
;91
:109
-124
.16.
Qi
T
, Cao
Y
. In translation: FcRn across the therapeutic spectrum
. Int J Mol Sci
. 2021
;22
(6
):3048
.17.
Ober
RJ
, Martinez
C
, Lai
X
, Zhou
J
, Ward
ES
. Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level
. Proc Natl Acad Sci U S A
. 2004
;101
(30
):11076
-11081
.18.
McCluskey
G
, Heestermans
M
, Peyron
I
, et al. A fully humanized von Willebrand disease type 1 mouse model as unique platform to investigate novel therapeutic options
. Haematologica
. 2025
;110
(4
):923
-937
.19.
Denis
C
, Methia
N
, Frenette
PS
, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis
. Proc Natl Acad Sci U S A
. 1998
;95
(16
):9524
-9529
.20.
Jumper
J
, Evans
R
, Pritzel
A
, et al. Highly accurate protein structure prediction with AlphaFold
. Nature
. 2021
;596
(7873
):583
-589
.21.
Sugio
S
, Kashima
A
, Mochizuki
S
, Noda
M
, Kobayashi
K
. Crystal structure of human serum albumin at 2.5 A resolution
. Protein Eng
. 1999
;12
(6
):439
-446
.22.
Fuller
JR
, Knockenhauer
KE
, Leksa
NC
, Peters
RT
, Batchelor
JD
. Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy
. Blood
. 2021
;137
(21
):2970
-2980
.23.
Huizinga
EG
, Tsuji
S
, Romijn
RA
, et al. Structures of glycoprotein Ibalpha and its complex with von Willlebrand factor A1 domain
. Science
. 2002
;297
(5584
):1176
-1179
.24.
Buyue
Y
, Whinna
HC
, Sheehan
JP
. The heparin-binding exosite of factor IXa is a critical regulator of plasma thrombin generation and venous thrombosis
. Blood
. 2008
;112
(8
):3234
-3241
.25.
Muczynski
V
, Casari
C
, Moreau
F
, et al. A factor VIII-nanobody fusion protein forming an ultrastable complex with VWF: effect on clearance and antibody formation
. Blood
. 2018
;132
(11
):1193
-1197
.26.
Aymé
G
, Adam
F
, Legendre
P
, et al. A novel single-domain antibody against von Willebrand factor A1 domain resolves leukocyte recruitment and vascular leakage during inflammation-brief report
. Arterioscler Thromb Vasc Biol
. 2017
;37
(9
):1736
-1740
.27.
Lenting
PJ
, Westein
E
, Terraube
V
, et al. An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation
. J Biol Chem
. 2004
;279
(13
):12102
-12109
.28.
Chaudhury
C
, Mehnaz
S
, Robinson
JM
, et al. The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan
. J Exp Med
. 2003
;197
(3
):315
-322
.29.
Haberichter
SL
. von Willebrand factor propeptide: biology and clinical utility
. Blood
. 2015
;126
(15
):1753
-1761
.30.
Haberichter
SL
. VWF propeptide in defining VWD subtypes
. Blood
. 2015
;125
(19
):2882
-2883
.31.
Schulte
S
. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII
. Thromb Res
. 2013
;131
(suppl 2
):S2
-S6
.32.
Vanderschuren
K
, Arranz-Gibert
P
, Khang
M
, et al. Tuning protein half-life in mouse using sequence-defined biopolymers functionalized with lipids
. Proc Natl Acad Sci U S A
. 2022
;119
(4
):e2103099119
.33.
Yang
B
, Kim
JC
, Seong
J
, Tae
G
, Kwon
I
. Comparative studies of the serum half-life extension of a protein via site-specific conjugation to a species-matched or -mismatched albumin
. Biomater Sci
. 2018
;6
(8
):2092
-2100
.34.
Swystun
LL
, Michels
A
, Lillicrap
D
. The contribution of the sinusoidal endothelial cell receptors CLEC4M, stabilin-2, and SCARA5 to VWF-FVIII clearance in thrombosis and hemostasis
. J Thromb Haemost
. 2023
;21
(8
):2007
-2019
.35.
O’Sullivan
JM
, Ward
S
, Lavin
M
, O’Donnell
JS
. von Willebrand factor clearance - biological mechanisms and clinical significance
. Br J Haematol
. 2018
;183
(2
):185
-195
.36.
Lenting
PJ
, Christophe
OD
, Denis
CV
. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends
. Blood
. 2015
;125
(13
):2019
-2028
.37.
Borvak
J
, Richardson
J
, Medesan
C
, et al. Functional expression of the MHC class I-related receptor, FcRn, in endothelial cells of mice
. Int Immunol
. 1998
;10
(9
):1289
-1298
.38.
Akilesh
S
, Christianson
GJ
, Roopenian
DC
, Shaw
AS
. Neonatal FcR expression in bone marrow-derived cells functions to protect serum IgG from catabolism
. J Immunol
. 2007
;179
(7
):4580
-4588
.39.
Terglane
J
, Menche
D
, Gerke
V
. Acidification of endothelial Weibel-Palade bodies is mediated by the vacuolar-type H+-ATPase
. PLoS One
. 2022
;17
(6
):e0270299
.40.
Yamashiro
DJ
, Maxfield
FR
. Regulation of endocytic processes by pH
. Trends Pharmacol Sci
. 1988
;9
(6
):190
-193
.41.
Tosetto
A
, Rodeghiero
F
, Castaman
G
, et al. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD)
. J Thromb Haemost
. 2006
;4
(4
):766
-773
.42.
James
P
, Leebeek
F
, Casari
C
, Lillicrap
D
. Diagnosis and treatment of von Willebrand disease in 2024 and beyond
. Haemophilia
. 2024
;30
(suppl 3
):103
-111
.43.
Regling
K
, Sidonio
RF
. Factor VIII stimulants and other novel therapies for the treatment of von Willebrand disease: whatʹs new on the horizon?
. Expert Opin Pharmacother
. 2024
;25
(11
):1427
-1438
.44.
Chion
A
, Byrne
C
, Atiq
F
, et al. The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1
. Blood
. 2024
;144
(13
):1445
-1456
.© 2025 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2025
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal